Cancer patients who receive chemotherapy as part of their treatment may be at increased risk for cardiotoxicity and vascular disease. New cancer therapies may interfere with normal heart and vascular function. Specialists trained in cardio-oncology can detect these adverse reactions at an early stage and develop personalized treatment plans to avoid serious cardiovascular complications.
UR Medicine Heart & Vascular is collaborating with the James P. Wilmot Cancer Center to offer our unique Cardio-Oncology Program—the only one of its kind in Upstate New York.
Led by Eugene Storozynsky, MD, PhD, a cardiologist who specializes in heart failure and transplantation, the program identifies patients who have cancer and may be at an increased risk for chemotherapy-induced cardiotoxicity, with the goal of minimizing this reaction to chemotherapy.
We use innovative imaging techniques such as strain echocardiography, cardiac MRI, angiography, and associated endomyocardial biopsy to identify patients and address their risk factors to minimize potential cardiotoxicity. And, for those who have already developed cardiotoxicity, we’ll treat it.
If you or a loved one is a cancer patient receiving chemotherapy and you have concerns about cardiotoxicity, contact the UR Medicine Cardio-Oncology Program at (585) 275-2475.
Today, there are nearly 25 chemotherapeutic agents that may be associated with heart dysfunction. Plus, when cancer patients develop chemotherapy cardiotoxicity, it may limit the ability of oncologists to use chemotherapy agents known to eradicate cancer and limit cancer's recurrence
When we use medications such as selective ACE-inhibitors, ARB's, beta blockers and aldosterone blockers to protect a patient's heart, they can continue receiving necessary chemotherapeutic agents while minimizing their risk for developing heart disease.